ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?

On Nov. 12, 2025, ARK Investment Management disclosed in an SEC filing that it reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by approximately 400,000 shares.According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold 395,617 shares of CRISPR Therapeutics AG during the third quarter. Its post-trade stake totaling 9,786,973 shares was worth $634.29 million as of Sept. 30, 2025.CRISPR Therapeutics AG is a leading biotechnology company specializing in the development of gene-editing therapies for serious diseases, leveraging its proprietary CRISPR/Cas9 platform. The company’s strategy centers on advancing a diversified pipeline across hemoglobinopathies, oncology, and regenerative medicine, supported by strategic partnerships with major industry players. Its competitive edge lies in its scientific leadership in gene editing and its ability to address high unmet medical needs with innovative, potentially curative therapies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool